Current Report Filing (8-k)
26 Januar 2015 - 8:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): December 22, 2014
Ardelyx, Inc.
(Exact
name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
001-36485 |
|
26-1303944 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
34175 Ardenwood Blvd.
Fremont, CA 94555
(Address of Principal Executive Offices)
(510) 745-1700
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 7.01. REGULATION FD DISCLOSURE
In December 2014, each of Michael Raab, President and Chief Executive Officer of Ardelyx, Inc. (Ardelyx), Mark Kaufmann, Chief
Financial Officer of Ardelyx, Jeffrey Jacobs, Vice President, Chemistry of Ardelyx, George Jue, Vice President, Finance and Operations of Ardelyx, David Rosenbaum, Senior Vice President, Drug Development of Ardelyx, Elizabeth Grammer, Vice President
and General Counsel of Ardelyx and Peter Schultz, Co-founder and Director of Ardelyx entered into a written trading plan in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Mr. Raabs plan authorizes the sale of up to 39,900 shares of common stock of Ardelyx and ends on June 30, 2015, unless
terminated earlier. Mr. Kaufmanns plan authorizes the sale of up to 30,000 shares of common stock of Ardelyx and ends on June 30, 2015, unless terminated earlier. Dr. Jacobss plan authorizes the sale of up to 39,888 shares
of common stock of Ardelyx plus shares purchased pursuant to the Ardelyx Employee Stock Purchase Plan and ends on June 30, 2015, unless terminated earlier. Mr. Jues plan authorizes the sale of up to 21,500 shares of common stock of
Ardelyx and ends on December 15, 2015, unless terminated earlier. Dr. Rosenbaums plan authorizes the sale of up to 10,110 shares of common stock of Ardelyx and ends on June 15, 2015, unless terminated earlier.
Ms. Grammers plan authorizes the sale of up to 10,000 shares of common stock of Ardelyx plus shares purchased pursuant to the Ardelyx Employee Stock Purchase Plan and ends on June 29, 2015, unless terminated earlier.
Dr. Schultzs plan authorizes the sale of up to 240,000 shares of common stock of Ardelyx and ends on July 31, 2015, unless terminated earlier.
Trades under the plans will not occur prior to the 30-day waiting period consistent with Ardelyxs Insider Trading Compliance Policy.
Reports of the details of actual sales under the plans will be filed by the appropriate plan participant in accordance with the Securities and Exchange Commissions regulations. Each plan participant may from time to time buy or sell
Ardelyxs securities outside of such participants respective plan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: January 26, 2015 |
|
|
|
ARDELYX, INC. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Mark Kaufmann |
|
|
|
|
Name: Mark Kaufmann |
|
|
|
|
Title: Chief Financial Officer |
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Ardelyx (NASDAQ:ARDX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024